The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
- Sponsor
- Ain Shams University
- Study ID
- NCT03895229
- Phase
- PHASE1
- Status
- Completed
Conditions
- Diabetes Mellitus
- Pharmacodynamics
- Pharmacokinetics
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Accepted
Interventions
- Empagliflozin 10 MG Oral Tablet [Jardiance] — DRUGEmpagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
Study Details
An Open-label, One way, Two period Comparative study To Determine The effect of Morning Versus Evening administration of Empagliflozin 10mg on Its Pharmacokinetics And Pharmacodynamics in Healthy Adults
Key Dates
- Start date
- Oct 1, 2018
- Status verified
- Apr 2019
- Primary completion
- Oct 19, 2018
- Completion
- Oct 26, 2018
Study Design
- Enrollment
- 16 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Experimental ArmSubjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet \[Jardiance\]
Primary Outcome Measure
Maximum drug concentration in plasma (Cmax) [ Time Frame: 0 up to 4 hours ]
Related Studies
- Genetic Studies of Insulin and DiabetesRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical StudyRecruiting · Washington University School of Medicine · St Louis, Missouri
- Inflammation, Diabetes, Ethnicity and Obesity CohortRecruiting · University of California, San Francisco · San Francisco, California
- Early Tracking of Childhood Health Determinants (ETCHED) StudyRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona